

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 4

Date: 22/07/2022

Location: Virtually via Zoom

Minutes: Confirmed

| Committee members present: | | |
|-----------------------------------|--|---------------------------|
| Alison Cameron (Chair) | | (Present for notes 1 – 8) |
| Ranjit Manchanda (Topic Advisor) | | (Present for notes 1 – 8) |
| Victoria Barber | | (Present for notes 1 – 8) |
| Adam Brentnall | | (Present for notes 1 – 8) |
| Rebecca Bowen | | (Present for notes 1 – 8) |
| Gareth Evans | | (Present for notes 1 – 8) |
| Glenn McCluggage | | (Present for notes 1 – 8) |
| Tracie Miles | | (Present for notes 1 – 8) |
| Davina Moses | | (Present for notes 1 – 8) |
| Fiona Robb | | (Present for notes 1 – 8) |
| Adam Rosenthal | | (Present for notes 1 – 8) |
| Lucy Side | | (Present for notes 2 – 8) |
| Joanne Stanford | | (Present for notes 1 – 8) |

| In attendance: | | |
|-----------------------|----------------------------|---------------------------|
| Katharina Dworzynski | Guideline Lead | (Present for notes 1 – 8) |
| Nathan Bromham | Senior Systematic Reviewer | (Present for notes 1 – 8) |
| Laura Berg | Systematic Reviewer | (Present for notes 1 – 8) |
| Paul Jacklin | Senior Health Economist | (Present for notes 2 – 8) |
| Neil Ryan | Clinical Fellow | (Present for notes 1 – 8) |
| Adam Storrow | Business Analyst | (Present for notes 3 – 8) |
| Georgina Winney | Business Administrator | (Present for notes 1 – 4) |
| Apologies: | | |
| Vishakha Tripathi | Committee member | |
| Judith Hayward | Committee member | |
| Steve Pilling | Clinical Advisor | |

| | |
|---------------|---------------------------------|
| Suhayl Kassam | Systematic Reviewer |
| Hayley Shaw | Project Manager |
| Eric Slade | Senior Health Economist |
| Nick Staples | Guideline Commissioning Manager |

1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members and attendees to the 4th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. No new declarations were made. The chair confirmed that previously declared interest did not preclude members from participating.

3. Minutes of the last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

4. Morning presentations

The Chair introduced Katharina Dworzynski, Guideline Lead who led on edited recommendation of 1.1.2 and 1.1.9. The committee discussed the issues raised by the editor and signed off changes to the recommendations.

Laura Berg, Systematic Reviewer, Nathan Bromham, Senior Systematic Reviewer and Paul Jacklin, Senior Health Economist, presented the clinical and economic evidence related to review question 6.1: 'What are the benefits and risks of surveillance for women at increased risk of familial ovarian cancer?' and review question 6.2: 'How effective are different methods of surveillance for women at increased risk of familial ovarian cancer?'. Question 6.1 was supported by Rebecca Bowen, Topic Group Lead and question 6.2 was supported by Victoria Barber, Topic Group Lead.

Adam Storrow, Business Analyst, gave a presentation on the resource impact for the guideline and took questions from the committee.

5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

6. Afternoon presentations

The Chair introduced Laura Berg, Systematic Reviewer who presented the protocols for topic 8 – risk reducing surgery. Laura presented on the following protocols:

- 8.1: How effective is risk-reducing surgery for women at increased risk of familial ovarian cancer (also considering risk threshold, age and extent and types of surgery)?
- 8.2: What pathological protocol for handling specimens from risk reducing surgery should be followed for risk-reducing surgery for women at increased risk of familial ovarian cancer?

The committee discussed the details of the protocol and signed them off.

Nathan Bromham, Senior Systematic Reviewer, presented the protocol for draft review question 8.3: What are the benefits and risks of hormone replacement therapy after risk-reducing surgery for women at increased risk of familial ovarian cancer? And 2.1: ‘What is the most effective configuration of services for referral, risk assessment and risk management for women at increased risk of ovarian cancer (including fertility, menopause and psychological support services)?’

7. Questions and discussion

The committee discussed:

- The evidence presented for evidence review questions 6.1 and 6.2
- The population characteristics and potential subgroups, interventions and outcomes for protocol questions 8.1, 8.2, 8.3 and 2.1

8. Any other business and summary of actions

Katharina Dworzynski summarised the actions set at the meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 30/08/2022

Location of next meeting: Hybrid meeting – To be held at 2 Redman Place Offices and via Zoom.